Director Field Medical
Fennec
Huntingdon Valley, Pennsylvania
Donna has 26 years experience as an oncology APRN and a is board certified Clinical Nurse Specialist, with 3 publications, including the Clinical Nurse Specialist Journal. Over the last 11 years she has worked in industry, supporting the launches of 7 oncology drugs, most recently a novel therapy to prevent cisplatin induced ototoxicity with Fennec Pharmaceuticals.
Financial Disclosures: Fennec Pharmaceuticals: Employment (Ongoing)
Non-Financial Disclosures: I do not have any relevant non-financial relationships with anything to disclose.
IU120 - Use of PEDMARK to Reduce Cisplatin-Induced Ototoxicity in Pediatric Patients
Thursday, April 20, 2023
1:50 PM – 2:20 PM PDT
IU205 - Use of PEDMARK to Reduce Cisplatin-Induced Ototoxicity in Pediatric Patients
Friday, April 21, 2023
12:00 PM – 12:30 PM PDT